BioSerenity Funding, Investors & Competitors

BioSerenity has raised $121M across 5 funding rounds, most recently a $26M undisclosed-stage round in November 2023.

Last BioSerenity funding round

$26M

Undisclosed stage · Nov 2023

Cumulative funding BioSerenity raised

$121M

across 5 funding rounds

Key investors in BioSerenity

  • Idinvest Partners
  • Bpifrance
  • LBO France
  • Kurma Partners
  • WILCO
  • Innovation Capital
  • Dassault Systemes
  • Jolt Capital

BioSerenity Overview

About BioSerenity

BioSerenity is a Paris-based neurotech firm specializing in epilepsy diagnostics. Its Neuronaute wearable records 24/7 EEG with video and motion tracking, anonymizing data for researchers at Institut du Cerveau et Moelle Épinière. Launched in 2014, the system analyzes 10,000 seizures from 2,000 patients, aiding AI model training. BioSerenity expands to sleep disorders, serving 50 French hospitals and exporting to the US.


Founded

2014

HQ

FranceParis

Status

Privately held

Customer focus

B2B

Revenue model

Product sales, Subscription

BioSerenity Funding History

BioSerenity has raised a total of $121M across 5 funding rounds.

BioSerenity's first fundraising round was a $200K pre-seed round in September 2014. The most recent completed round was a $26M undisclosed-stage round in November 2023.

BioSerenity funding rounds

BioSerenity funding rounds
DateStageInvestorsRaisedDeal Summary
Nov 2023Undisclosed stageJolt Capital (lead)$26MBioSerenity, founded in 2014, specializes in connected medical devices and software for electroencephalography (EEG), extending to sleep disorders and neurological diagnostics. The company offers products like Neuronaute and Icecap hardware, CE-marked and FDA-cleared, along with AI-based diagnostic software (LR), protected by over 30 international patents. It serves more than 300 partners, treats 150,000 patients annually, and has reached over 1 million patients total by July 2023. On November 13, 2023, Jolt Capital, a private equity firm focused on European deeptech growth investments, announced a €24 million (approximately $25.65M-$26.1M USD) investment in BioSerenity. This private equity round brings the company's total funding to $119.87M across 9 rounds. Jolt Capital is the sole investor listed for this round, aligning with its strategy in advanced healthcare data technologies. The funding supports acceleration of international expansion, building on key markets in France and the United States while targeting Europe, deployment of advanced AI for improved diagnostics in telemedicine, and strengthening of the management team, including the appointment of Vincent Marcel as CEO. BioSerenity positions itself as a leader in neurology and sleep disorder solutions with market-proven technologies. The investment underscores investor confidence in BioSerenity's proprietary tech amid healthcare innovation needs, with Jolt Capital highlighting its fit for significant financing to drive development.
Jun 2019Series BDassault Systemes (lead); LBO France; Idinvest Partners; Bpifrance$74MBioSerenity, a French medtech company specializing in connected medical devices and remote-monitoring solutions for patients with cardiac, neurological, and sleep disorders, raised approximately $56-73 million in a Series B funding round on June 18-19, 2019. The round was led by Dassault Systèmes, with participation from Bpifrance, Idinvest Partners (also referred to as IDInvest Partners), and LBO France. Dassault Systèmes took a non-controlling interest in BioSerenity as part of this investment, aligning with their 2019 strategy to expand in life sciences and healthcare through targeted acquisitions and stakes in innovative firms. This move complemented other major activities that year, such as the acquisition of Medidata Solutions, positioning life sciences as their second-largest revenue source. The funding occurred amid a robust month for medical devices venture financing, totaling $661.16M globally, with BioSerenity's deal contributing significantly to the top five totaling $294.34M.
Sep 2017Series ALBO France (lead); Idinvest Partners; Bpifrance; Innovation Capital$18MBioSerenity develops a platform connecting patients with healthcare providers via smart and connected clothes in the digital health sector based in France. LBO France led the investment in BioSerenity in 2017, with the company listed as in portfolio and classified under private equity. The round amount was approximately $17.8 million. BioSerenity has raised a total of $119.87 million over 9 rounds, with investors including LBO France, Bpifrance, IDInvest Partners, JOLT Capital, and SCOR Life & Health Ventures.
Nov 2015SeedKurma Partners (lead); Idinvest Partners$3MBioSerenity is a French startup specializing in wearable medical device solutions for epilepsy diagnosis and medical diagnostics, launched in January 2014 and located within the Brain and Spine Institute of Paris. The company raised 3 million Euros in a seed round from Kurma Diagnostics and Idinvest Partners. Kurma Partners led the investment, marking the first investment from their newly launched diagnostics fund.
Sep 2014Pre-seedWILCO$200K-

Who has invested in BioSerenity?

8 investors have backed BioSerenity across its funding rounds, including Idinvest Partners, Bpifrance, LBO France, Kurma Partners, WILCO and Innovation Capital.

Lead investors include Jolt Capital, Dassault Systemes, LBO France and Kurma Partners.


BioSerenity Investors

Investors in BioSerenity by funding rounds participated
InvestorHQRoundsRoleFirst check
Idinvest PartnersFranceParis3ParticipantNov 2015
LBO FranceFranceFrance2LeadSep 2017
BpifranceFranceParis2ParticipantSep 2017
Jolt CapitalFranceParis1LeadNov 2023
Kurma PartnersFranceParis1LeadNov 2015
WILCOFranceParis1ParticipantSep 2014

This data is available for Pro users. Sign up to see all 8 BioSerenity investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Investments by BioSerenity

BioSerenity has invested in 1 company to date.

Latest investment by BioSerenity was on April 5th 2024. BioSerenity invested in BOYDSense in their $8M Series A round.


Latest Investments by BioSerenity

BOYDSense
Description
BOYDSense is a South San Francisco-headquartered biotechnology company developing non-invasive breath analysis devices for chronic disease diagnostics. The firm captures volatile organic compounds in exhaled breath to detect biomarker patterns for conditions like asthma, diabetes, and metabolic disorders. Founded in 2015, BOYDSense employs metabolomics platforms combining sensors, AI algorithms, and cloud-based analytics for real-time monitoring. Its tools target clinical settings, consumer wellness, and telemedicine, partnering with healthcare providers to enable affordable at-home testing.
HQ CountryUnited States
HQ City
San Francisco, CA
Deal Date5 Apr 2024
RoundSeries A
Raised$8M
InvestorsEuropean Innovation Council; Ambrosia Investments; Jolt Capital; Swiss Diabetes Venture Fund; Sweet Ventures; Alpha MOS
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all BioSerenity investments and their VC round multiples.

Start Free Trial

BioSerenity Competitors

BioSerenity competitors include listed companies like IQVIA, ICON plc and Privia Health, and private ones like Innovaccer, NantHealth and Unite Us.

Public and private companies comparable to BioSerenity
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
IQVIAUnited StatesUnited StatesPublicly listed$16B$3.4B$44B3.4x
ICON plcUnited StatesUnited StatesPublicly listed$8.3B$816M$13B1.9x
InnovaccerUnited StatesSan Francisco, CAPrivate$250M-$3.5B13.8x
Privia HealthUnited StatesUnited StatesPublicly listed$2.1B$44M$2.6B0.9x
NantHealthUnited StatesLos Angeles, CAPrivate$58M-$2B-
Unite UsUnited StatesNew York City, NYPrivate--$1.6B-

BioSerenity Public Comps

BioSerenity is still privately-owned, but its public comps include IQVIA, Veeva, IDEXX Laboratories, Roper Technologies, GE HealthCare, Revvity, Solventum, Tempus AI, ICON plc and Pro Medicus.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
IQVIA$16B$3.4B3.6x3.4x17.2x14.8x
Veeva$3.2B$965M11.1x10.2x36.9x22.4x
IDEXX Laboratories$4.3B$1.5B9.5x8.9x27.1x24.9x
Roper Technologies$7.9B$3.2B6.1x5.7x15.2x14.6x
GE HealthCare$21B$3.7B1.8x1.8x10.1x10.0x
Revvity$2.9B$735M6.5x6.6x25.4x21.0x
Solventum$8.3B$2.5B2.4x2.4x7.8x8.9x
Tempus AI$1.3B($131M)12.0x10.1x(116.0x)346.0x

This data is available for Pro users. Sign up to see all BioSerenity competitors and their valuation data.

Start Free Trial

Common questions about BioSerenity

When was BioSerenity founded?BioSerenity was founded in 2014.
Where is BioSerenity headquartered?BioSerenity is headquartered in Paris, France.
Is BioSerenity publicly listed?No, BioSerenity is a private, VC-backed company.
How much funding has BioSerenity raised?BioSerenity has raised $121M across 5 funding rounds.
What was BioSerenity's last funding round?BioSerenity's last funding round was a $26M undisclosed-stage round in November 2023, led by Jolt Capital.
Who are BioSerenity's investors?BioSerenity's investors include Idinvest Partners, LBO France, Bpifrance, Jolt Capital, Kurma Partners, WILCO, Innovation Capital and Dassault Systemes.
Which companies are comparable to BioSerenity?Companies comparable to BioSerenity include IQVIA, ICON plc, Innovaccer, Privia Health, NantHealth and Unite Us.
How many companies has BioSerenity invested in?BioSerenity has invested in 1 company, including BOYDSense.
What was BioSerenity's last investment?In April 2024, BioSerenity invested in BOYDSense's $8M Series A alongside European Innovation Council, Ambrosia Investments, Jolt Capital and 3 other investors.

See companies similar to BioSerenity

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial